10-K: AIM ImmunoTech Faces Delisting Risk Amidst Pancreatic Cancer Focus

AIM ImmunoTech's 2025 annual report highlights a strategic pivot to late-stage pancreatic cancer for Ampligen, despite ongoing financial losses and NYSE American delisting concerns.

Summary

• AIM ImmunoTech is strategically focusing its efforts on the development of Ampligen for the treatment of late-stage pancreatic cancer, believing it to be the most lucrative path.
• The company reported a net loss of approximately $13,958,000 for the year ended December 31, 2025, an improvement from a $17,320,000 net loss in 2024.
• As of December 31, 2025, the company had a stockholders' deficit of approximately ($9,783,000), which is significantly below the NYSE American's minimum requirement of $6,000,000 for continued listing.
• The company received a notice of noncompliance from the NYSE American on December 11, 2024, regarding its stockholders' equity, with a deadline of June 11, 2026, to regain compliance.
• Trading in the company's common stock was suspended on April 4, 2025, due to its price dropping below $0.10 per share; a 1-for-100 reverse stock split was effected on June 10, 2025, and trading was reinstated on June 17, 2025.
• The Phase 2 DURIPANC study evaluating Ampligen in combination with durvalumab for metastatic pancreatic cancer has enrolled 18 patients, with promising progression-free survival and overall survival continuing to be observed, and no significant toxicity reported.
• An agreement was announced in March 2026 with Thermo Fisher Scientific's PPD clinical research business to design AIM's anticipated Phase 3 clinical trial for Ampligen in late-stage pancreatic cancer.
• The AMP-270 Phase 2 pancreatic cancer study has been placed on hold and suspended, pending additional data from the ongoing DURIPANC clinical trial.
• Final Clinical Study results from the AMP-518 Phase 2 study for Post-COVID conditions were posted in January 2025, supporting Ampligen as a potential therapeutic for moderate-to-severe Post-COVID fatigue.
• Commercial sales of Alferon N Injection remain halted due to a lack of finished goods inventory, with no definitive timetable to resume production.
• A rights offering completed on March 6, 2026, raised approximately $1,800,000 in gross proceeds.
• Class E and F Warrants are expected to be reclassified from liability to equity in the first quarter of 2026 due to a stock dividend, which is anticipated to significantly increase stockholders' equity.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning filing. The company faces severe financial distress, including substantial doubt about its going concern ability and ongoing delisting risks. While there are promising clinical results for Ampligen in pancreatic cancer, the numerous terminated trials due to funding and the halted production of Alferon N Injection highlight significant operational and financial instability.

Positives

• Strategic focus on late-stage pancreatic cancer for Ampligen targets a large market with unmet medical need and relatively little clinical competition.
• Promising progression-free survival and overall survival, along with no significant toxicity, have been observed in the ongoing Phase 2 DURIPANC study for metastatic pancreatic cancer.
• An agreement with Thermo Fisher Scientific's PPD business to design a Phase 3 clinical trial for Ampligen in late-stage pancreatic cancer indicates advancement towards pivotal studies.
• The company holds broad combination therapy patents in the United States, Japan, and Europe for Ampligen in oncology, enhancing intellectual property protection.
• Ampligen has received Orphan Drug Designations for pancreatic cancer in both the U.S. (7 years market exclusivity) and the European Union (10 years market exclusivity).
• Phase 2 study results for Ampligen in Post-COVID conditions (AMP-518) support its potential as a therapeutic for moderate-to-severe fatigue, showing a statistically significant signal (p <0.02) in a subset of patients.
• A legal fee settlement in 2025 resulted in $3,041,000 of previously billed fees being forgiven, contributing to other income and reducing accounts payable.
• The reclassification of Class E and F Warrants from liability to equity in Q1 2026 is expected to significantly increase stockholders' equity, which is crucial for NYSE American listing compliance.
• Net loss decreased by 19% in 2025 compared to 2024, driven by reductions in general and administrative and research and development expenses.
• Successful execution of a 1-for-100 reverse stock split and subsequent reinstatement of trading on the NYSE American after a delisting for low selling price.

Negatives

• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses, net cash used in operating activities, and a working capital deficit.
• The stockholders' deficit of ($9,783,000) as of December 31, 2025, is significantly below the NYSE American's $6,000,000 minimum requirement, posing a continued delisting risk.
• Multiple clinical trials, including the Phase 2 AMP-270 pancreatic cancer study, a Phase 2 advanced recurrent ovarian cancer study, a Phase 1 study for metastatic triple-negative breast cancer, and a Phase 2 study for refractory melanoma, were suspended or terminated due to funding issues or strategic shifts.
• Commercial sales of Alferon N Injection are halted due to a lack of finished goods inventory, with no definitive timetable to resume production or identify a contract manufacturing organization (CMO).
• The company has reached its lifetime cap of $20,000,000 for selling net operating losses under the New Jersey Technology Business Tax Certificate Transfer Program, eliminating this source of funding.
• Proceeds from the sale of marketable securities significantly decreased to $2,322,000 in 2025 from $5,623,000 in 2024.
• A loss of $3,977,000 was recognized from warrant issuance in 2025.
• Revenues from the Ampligen Cost Recovery Program decreased by $82,000 in 2025.
• The company has limited product liability and clinical trial insurance coverage.
• Operating in foreign countries, such as Argentina, presents risks including currency devaluation and difficulties in enforcing intellectual property rights, which have delayed Ampligen commercialization.

Risks

• The company has a history of losses, expects to continue incurring losses, and may not achieve or sustain profitability, raising substantial doubt about its ability to continue as a going concern.
• Non-compliance with NYSE American continued listing requirements, specifically the stockholders' equity rule, could lead to delisting of its common stock.
• The company will require additional financing, which may not be available, and any future equity issuances could significantly dilute current ownership.
• The investigational nature of Ampligen and other related technologies means they are subject to rigorous and lengthy regulatory approval processes, with no assurance of timely approval or success.
• Potential product liability claims from the use of Ampligen or Alferon N Injection could negatively affect future operations, and the company has limited product liability and clinical trial insurance.
• Uncertainty exists regarding health care reimbursement for the company's products, which could impact commercialization success.
• Risks are associated with handling and disposing of hazardous materials, potentially leading to liabilities.
• Failures of the company's information technology infrastructure could have a material adverse effect on operations.
• The loss of services of key personnel could hurt the company's chances for success.
• Financial statements rely on estimates, judgments, and assumptions in accordance with GAAP, which inherently contain uncertainties and could lead to material variations in actual results.
• Assets held at financial institutions may exceed FDIC insurance coverage, posing a risk of loss.
• Ampligen's development is subject to significant risks, including potential ineffectiveness, adverse side effects, failure to receive regulatory clearances, manufacturing difficulties, or being uneconomical to market.
• The development of Alferon N Injection is subject to significant risks, and its commercial sales are currently halted.
• Possible side effects from Ampligen or Alferon N Injection could adversely affect potential revenues and physician/patient acceptability.
• It is not possible to predict the future of COVID-19 and related Post-COVID Conditions, and there is no assurance that Ampligen will be effective or widely adopted for these treatments.
• Operating in foreign countries carries risks, including difficulties in enforcing intellectual property rights and adverse effects from local economic conditions (e.g., Argentine peso devaluation).
• The company may not be profitable unless it can protect its patents and/or receive approval for additional pending patents, and the patent position of biotechnology firms is highly uncertain.
• There is no assurance that the company will be able to obtain necessary licenses if it cannot enforce patent license rights it may hold, or that third parties will adequately enforce their licensed rights.
• There is no guarantee that the company's trade secrets will not be disclosed or known by competitors.
• The company cannot predict what additional studies, testing, or information may be required by the FDA, making it difficult to estimate timelines, costs, and efforts for project completion.
• There are no long-term agreements with suppliers for Ampligen materials, and a limited number of raw material suppliers, posing a risk to manufacturing continuity.
• The company has limited manufacturing experience for Ampligen and Alferon N Injection, and there is no assurance that limited-scale production can successfully transition to commercial, large-scale production at acceptable costs.
• Inability to achieve licensing, collaboration, and/or joint ventures could hinder the marketing strategy for Ampligen.
• Limited marketing and sales capability means dependence on existing and future third-party distribution agreements, with no assurance of their success.
• Rapid technological change in the pharmaceutical and biotechnology industries may render the company's products obsolete or non-competitive.
• The company's products may be subject to substantial competition from larger pharmaceutical companies with greater resources.
• The market price of the company's stock may be adversely affected by market volatility and broad industry factors.
• Sales of a significant number of common stock shares in public markets, or the perception of such sales, could depress the market price.
• Provisions in the Certificate of Incorporation and Delaware law (e.g., preferred stock issuance, lack of cumulative voting, advance notice requirements, stockholder rights plan) could defer changes in management or discourage acquisition offers.
• Actions by activist investors could negatively affect the business, financial condition, and operating results through costly proxy contests, disruption, and perceived instability.
• Increasing regulation regarding responses to cybersecurity incidents could subject the company to additional liability and reputational harm.

Future Outlook

The company intends to focus its efforts on the development of Ampligen for late-stage pancreatic cancer, anticipating a Phase 3 clinical study following the ongoing Phase 2 DURIPANC trial, with detailed data expected later this year. It plans to pursue a study for a potential avian influenza combination therapy of Ampligen and AstraZenecas FluMist, seeking collaborative grants. Future trials for Post-COVID fatigue are expected to target subjects with moderate or worse fatigue. The company will work with its commercial partner, Filaxis, on Ampligen approval for pancreatic cancer in Argentina, shifting focus from Chronic Fatigue Syndrome due to economic conditions. There is no definitive timetable to resume production of Alferon N Injection. The company continues to seek a worldwide marketing partner for Ampligen and aims to complete the validation of its polymer production process with Sterling Pharma Solutions.

Management Comments

• "Of all the opportunities a wide-spectrum therapeutic such as Ampligen has, pancreatic cancer treatment is the path that will potentially lead to the most lucrative outcome."
• "While Ampligen showed positive safety and efficacy in trials involving other solid tumor types, we believe that pancreatic cancer presents the best business opportunity."
• "AIM strongly believes that such a Phase 3 study will be possible following the ongoing Phase 2 clinical study evaluating Ampligen in combination with AstraZenecas anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer patients."
• "We believe that this pre-clinical and clinical work to date — combined with the ever-growing threat of Avian influenza — strongly supports our decision to move forward with this second Ampligen and FluMist study in humans."
• "The results support our belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would be the likely subject population for any follow-up clinical trial."
• "We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed to commercialize the many potential therapeutic aspects of our experimental drugs and our FDA approved drug Alferon N Injection."
• "If Ampligen has the broad-spectrum antiviral properties that we believe that it has, it could be a very valuable tool in treating variants of existing viral diseases, including COVID-19, or novel ones that arise in the future."
• "Unlike most developing therapeutics which attack the virus, Ampligen works differently. We believe that it activates antiviral immune system pathways that fight not just a particular virus or viral variant, but other similar viruses as well."

Industry Context

StockSavvy.ai notes that AIM ImmunoTech's strategic pivot to late-stage pancreatic cancer aligns with a broader industry trend of focusing on high-unmet-need oncology indications, which often attract significant investment and M&A activity, especially for Phase 3 ready assets. The company's emphasis on combination therapies with checkpoint inhibitors is also a common strategy in immuno-oncology to enhance efficacy. However, the halting of other trials due to funding issues highlights the intense capital requirements and competitive landscape in biotech, where larger players like Pfizer, Merck, and AstraZeneca (with whom AIM is collaborating) dominate. The challenges in commercializing Alferon N Injection and Ampligen in Argentina due to economic factors underscore the complexities of global market entry for smaller biopharma firms.

Comparison to Industry Standards

• The Objective Response Rate (ORR) of 45% and Clinical Benefit Rate (CBR) of 55% observed in platinum-sensitive recurrent ovarian cancer patients treated with Ampligen, pembrolizumab, and cisplatin are at the higher end of typical responses for standard platinum-based chemotherapy (30-50% ORR) in this setting, with a median Progression-Free Survival (PFS) of 7.8 months falling within the expected range of 6-12 months.
• The median overall survival of 19 months in the Ampligen group for locally advanced pancreatic cancer, compared to historical controls (7.5 and 12.5 months), suggests a significant improvement over the typical 6-12 month median OS for advanced pancreatic cancer patients receiving standard chemotherapy like FOLFIRINOX.
• The reported 'no significant toxicity' and 'high quality of life' in the DURIPANC study for pancreatic cancer are encouraging, as many current pancreatic cancer treatments are associated with severe side effects, making a favorable safety profile a potential competitive advantage.
• The statistically significant signal (p <0.02) observed in the AMP-518 study for Post-COVID fatigue in a subset of patients (Six-Minute Walk Test less than 205 meters) is a positive indicator for further development in a field that currently has limited approved therapies, suggesting Ampligen could address a significant unmet medical need.

Management Changes

Corporate Governance

Legal Proceedings

• **Jorgl v. AIM ImmunoTech, Inc. et al. (Delaware Court of Chancery)**: This action, challenging the Board's rejection of director nominations, concluded on February 3, 2025, with the Court denying both parties' motions for litigation fee shifting. The Court had previously denied Jorgl's motion for a preliminary injunction, and Jorgl subsequently decided not to proceed to trial or appeal.
• **AIM ImmunoTech, Inc. v. Tudor, et al. (United States District Court for the Middle District of Florida)**: This case concluded on April 4, 2025, when the Appellate court upheld the lower court's decision, which had granted-in-part motions for attorneys' fees and costs to Lautz and Jorgl. Judgments of $216,936 for Jorgl and $76,473 for Lautz were disbursed from a $366,762 bond posted by AIM, with $74,581 returned to AIM.
• **Kellner v. AIM ImmunoTech Inc. et al. (Supreme Court of the State of Delaware)**: This matter concluded on July 29, 2024. The Delaware Supreme Court affirmed in part and reversed in part a lower court opinion, holding certain bylaws adopted by the board were legally invalid and inequitable. The board subsequently revised the bylaws. Kellner's motion for reargument and request for fee applications were denied, and the case was closed.
• **BioLife**: The company's complaint against BioLife Plasma Services, L.P. was dismissed by the Superior Court of Pennsylvania on July 28, 2025, affirming a lower court order. The case is now concluded with no further action taken by either party.

Related Party Transactions

• The company has employment agreements with its Named Executive Officers (Thomas K. Equels, Robert Dickey IV, Peter W. Rodino III) detailing their compensation, including base salary, bonuses, and stock options.
• Stock options and warrants have been granted to the company's executive officers and directors as part of their compensation.
• Robert Dickey IV, the Chief Financial Officer, provides services through a consulting agreement with Foresite Advisors, LLC, a company wholly owned by him.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future equity raises, potential delisting from the NYSE American due to non-compliance with listing standards, and high volatility in the stock price. The recent reverse stock split addressed the low share price but not the underlying financial health. The reclassification of warrants to equity is a positive for the equity balance.
• **Employees**: Their employment and compensation are directly tied to the company's ability to secure sufficient funding and achieve commercial success. Executive officers voluntarily waived bonuses and options to conserve cash, indicating financial strain.
• **Customers/Patients**: Potential for new therapeutic options (Ampligen for pancreatic cancer, Post-COVID fatigue) if ongoing clinical trials are successful and regulatory approvals are obtained. However, the suspension or termination of several trials and the halted availability of Alferon N Injection limit current and future access to treatments.
• **Creditors**: The company's 'going concern' doubt and substantial debt raise concerns about its ability to meet financial obligations. The extension of a Promissory Note maturity date provides temporary relief but does not resolve the underlying liquidity issues.
• **Suppliers/Partners**: Dependence on third-party Contract Manufacturing Organizations (CMOs) and distributors creates risks if agreements cannot be secured or maintained on favorable terms. Delays in commercialization in Argentina impact partners like Filaxis.

Next Steps

• Design anticipated Phase 3 clinical trial for Ampligen in late-stage pancreatic cancer with Thermo Fisher Scientific's PPD business.
• Publication of detailed data from the Erasmus MC DURIPANC study later this year.
• Pursue a study of a potential avian influenza combination therapy of Ampligen and AstraZenecas FluMist.
• Seek collaborative grants from government and industry to defray the cost of the avian influenza study.
• Focus future clinical trial design for Post-COVID fatigue on subjects with moderate or worse fatigue.
• Work with Filaxis on an approval in Argentina for pancreatic cancer.
• Complete validation of the polymer production process with Sterling Pharma Solutions to enable manufacturing of more Ampligen polymer.
• Identify a new manufacturing approach and submit satisfactory stability and quality release data to the FDA to resume Alferon N Injection commercial sales.
• Regain compliance with NYSE American listing requirements by June 11, 2026, by increasing stockholders' equity to at least $6,000,000.
• Continue to seek a worldwide marketing partner for Ampligen.
• Continue efforts to understand existing data and advance new data for Ampligen to support future FDA filings.

Key Dates

Recommendation

StockSavvy.ai advises a 'Sell' recommendation due to the severe financial distress and high operational risks outlined in the filing. The company explicitly states 'substantial doubt about our ability to continue as a going concern' and faces potential delisting from the NYSE American due to a significant stockholders' deficit. While Ampligen shows promise in pancreatic cancer trials, the company's inability to fund multiple other promising trials, the halted production of its only FDA-approved product (Alferon N Injection), and the continuous need for dilutive capital raises create an extremely precarious investment environment. The positive clinical data, while encouraging, is overshadowed by the fundamental financial instability and the long, uncertain path to commercialization and profitability.

Keywords

Ampligen, pancreatic cancer, immuno-oncology, rintatolimod, NYSE American, delisting, going concern, clinical trials, Orphan Drug Designation, Post-COVID conditions, Alferon N Injection, biotechnology, pharmaceutical, capital raise, patents, durvalumab, FOLFIRINOX, dsRNA, TLR3 agonist, ME/CFS, reverse stock split